A SWATH-MS analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome peripheral blood mononuclear cell proteomes reveals mitochondrial dysfunction.
Sweetman, Eiren, Kleffmann, Torsten, Edgar, Christina et al. · Journal of translational medicine · 2020 · DOI
Quick Summary
Researchers examined immune cells from ME/CFS patients and compared them to healthy controls, looking at which proteins were present and in what amounts. They found that ME/CFS patients had different patterns of proteins, particularly ones involved in how cells produce energy (through structures called mitochondria). These findings suggest that people with ME/CFS may have problems with energy production in their cells, which could explain why fatigue and post-exertional malaise are core symptoms of the disease.
Why It Matters
This study provides molecular evidence that mitochondrial dysfunction and impaired energy production are real features of ME/CFS, rather than the disease being primarily psychological. Identifying specific protein abnormalities offers potential biomarkers that could help diagnose ME/CFS objectively and validate patients' experiences of genuine biological illness.
Observed Findings
Protein expression patterns in blood immune cells clearly separated 9 out of 11 ME/CFS patients from healthy controls.
Mitochondrial and energy production proteins were significantly dysregulated in ME/CFS patients compared to controls.
Proteins involved in oxidative stress regulation and antioxidant pathways showed abnormal patterns.
Immune and inflammatory pathway proteins were altered, consistent with previous ME/CFS research.
Proteins involved in DNA damage response, apoptosis, and protein degradation were differentially expressed.
Inferred Conclusions
ME/CFS involves measurable defects in cellular energy production at the molecular level.
Cells may be attempting to compensate for low ATP production by upregulating upstream metabolic pathways, leading to increased oxidative stress.
Mitochondrial dysfunction represents a real biological pathology in ME/CFS, supporting the development of protein-based diagnostic biomarkers.
The constellation of dysregulated proteins suggests ME/CFS involves multiple interconnected cellular processes beyond mitochondria alone.
Remaining Questions
Do these protein abnormalities appear in blood cells of patients with other fatigue-related conditions, or are they specific to ME/CFS?
What This Study Does Not Prove
This small exploratory study (11 patients) does not prove causation—it shows which proteins differ but not whether mitochondrial problems directly cause ME/CFS or develop as a consequence of the disease. The findings require replication in larger, more diverse populations before they can be used clinically as diagnostic tests. Additionally, the study examined only blood cells, so it does not clarify whether the same dysfunction occurs in other tissues.
Do the same mitochondrial dysfunctions occur in other tissue types (muscle, brain, etc.), and are they similar or different between individuals?
Which protein changes are primary causes of disease versus secondary consequences, and can this distinction guide therapeutic development?
How do these molecular findings relate to the characteristic symptom of post-exertional malaise—do proteins change differently after physical activity?